AXA Framlington Biotech GBP Z Acc (FUND:B784NS1) - Fund price


Fund Report

AXA Framlington Biotech Fund GBP Z Acc

Key Stats
Morningstar® CategorySector Equity Biotechnology
Manager NameLinden Thomson
Inception Date16/04/2012
NAV 23/06/2021GBX 470.80
Day Change-0.76%
12 Month Yield0.00%
ISINGB00B784NS11
Dividend FrequencySemi-Annually
Net Assets (mil) 31/05/2021417.07 GBP
Wrapper AvailabilityAll
Our Minimum Initial Investment1.00 Share
Pricing FrequencyDaily
Dealing Cut off Time10:45:00
Regular InvestmentYes
Actual Initial Charge0.00%
Exit Charge-
Custody ChargeYes
Ongoing Cost0.83%
AMC0.75%
Fund Rebate-

Morningstar Rating™

4 Stars

Morningstar® Sustainability Rating

Average

Average


Sustainability Rating as of 30/04/2021

Benchmarks

Fund Benchmark

NASDAQ Biotechnology TR USD

Morningstar® Benchmark

NASDAQ Biotechnology TR USD

Growth Of 10,000 (GBP) 31/05/2021

How has this security performed
201620172018201920202021
Fund-4.959.66-6.4219.3532.74-7.59
Category-3.9610.29-7.9620.2025.97-6.99
Benchmark-6.1811.10-3.2020.2822.52-3.42
  • Fund: AXA Framlington Biotech Fund GBP Z Acc
  • Category: Sector Equity Biotechnology
  • Benchmark: NASDAQ Biotechnology TR USD
Trailing Returns % (GBP) 23/06/2021
FundCatBmark
YTD-0.15-2.863.53
3 Years Annualised9.716.7611.23
5 Years Annualised15.4213.1214.79
10 Years Annualised18.4516.0018.65

Morningstar SRRI

Lower Risk
Higher Risk
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
Potentially Lower ReturnsPotentially Higher Returns
Source: Morningstar

Investment Objective

The aim of this Fund is to provide long-term capital growth. The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Manager selects shares based upon analysis of a company’s financial status, quality of its management, expected profitability and prospects for growth.

Portfolio Profile31/05/2021

Morningstar Style Box®

Equity Style

Large, Mid, SmallSize
Value, Blend, Growth
Style
Top Holdings
NameSector%
IncreaseDecreaseNew since last portfolio
Amgen Inc Healthcare6.42
Regeneron Pharmaceuticals Inc Healthcare6.40
Gilead Sciences Inc Healthcare5.24
DecreaseBiogen Inc Healthcare4.62
Moderna Inc Healthcare4.47
Asset Allocation %
LongShortNet
Stocks96.550.0096.55
Bonds0.000.000.00
Cash3.460.502.95
Other0.500.000.50
Top Stock Regions
Region%
United States87.54
Asia - Emerging4.67
Europe - ex Euro3.34
Eurozone2.45
United Kingdom2.01
Top Stock Sectors
Stock Sector%
Healthcare100.00
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2021 Morningstar. All rights reserved.